196TiPSGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer. (13th May 2019) - Boni, V; Alemany, C; Meisel, J L; Sinha, R; Sterrenberg, D; Tkaczuk, K H R; Wang, Y; Wang, Z; Han, H S